Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de documento
País/Região como assunto
Ano de publicação
Intervalo de ano de publicação
1.
Clin Diabetes ; 41(2): 198-207, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37092165

RESUMO

Advances in insulin delivery technologies have led to the development of tubeless "patch" systems; however, these devices still involve a level of complexity. We surveyed individuals with type 1 or type 2 diabetes to explore their attitudes and satisfaction after using the CeQur Simplicity insulin patch (SIP) for 2 months. Transition to the SIP yielded significant increases in respondents' overall treatment satisfaction, less diabetes burden, and improvements in psychological well-being compared with respondents' prior insulin delivery method.

2.
J Med Econ ; 21(3): 225-230, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28994334

RESUMO

BACKGROUND: It is estimated that one in 10 people in the US have a diagnosis of diabetes. Type 2 diabetes accounts for 95% of all cases in the US, with annual costs estimated to be $246 billion per year. This study investigated the impact of a glucose-measuring intervention to the burden of type 2 diabetes. OBJECTIVE: This analysis seeks to understand how professional continuous glucose monitoring (professional CGM) impacts clinical and economic outcomes when compared to patients who are not prescribed professional CGM. METHODS: This study utilized a large healthcare claims and lab dataset from the US, and identified a cohort of patients who were prescribed professional CGM as identified by CPT codes 95250 and 95251. It calculated economic and clinical outcomes 1 year before and 1 year after the use of professional CGM, using a generalized linear model. RESULTS: Patients who utilized professional CGM saw an improvement in hemoglobin A1C. The "difference-in-difference" calculation for A1C was shown to be -0.44%. There was no statistically significant difference in growth of total annual costs for people who used professional CGM compared to those who did not ($1,270, p = .08). Patients using professional CGM more than once per year had a -$3,376 difference in the growth of total costs (p = .05). Patients who used professional CGM while changing their diabetes treatment regimen also had a difference of -$3,327 in growth of total costs (p = .0023). CONCLUSION: Significant clinical benefits were observed for patients who used professional CGM. Economic benefits were observed for patients who utilized professional CGM more than once within a 1-year period or who used it during a change of diabetes therapy. This suggests that professional CGM may help decrease rising trends in healthcare costs for people with type 2 diabetes, while also improving clinical outcomes.


Assuntos
Automonitorização da Glicemia/economia , Efeitos Psicossociais da Doença , Diabetes Mellitus Tipo 2/fisiopatologia , Revisão da Utilização de Seguros , Avaliação de Resultados em Cuidados de Saúde , Current Procedural Terminology , Bases de Dados Factuais , Feminino , Hemoglobinas Glicadas/análise , Gastos em Saúde , Humanos , Seguro Saúde/economia , Masculino , Pessoa de Meia-Idade , Saúde da População , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA